Pancreatic ductal adenocarcinomas, by contrast, harbor NTRK1-3 fusions far less frequently (~0.3%), though modest enrichment was reported in RAS wild-type cases and individual case reports document durable responses to TRK inhibitors [69,123,124]. Here, NTRK1 is linked to pancreatic ductal adenocarcinoma.